New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

Boston, MA -- (SBWire) -- 01/24/2014 --The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

GlobalData believes that companies will be able to obtain small price increases over the established short-acting rFVIII and rFIX therapies, although due to the increasingly cost-conscious environment among EU healthcare authorities these opportunities will be limited over the forecast period.

View Full Report Details and Table of Contents

Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Spain Hemophilia A and B market.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Spain

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Hemophilia A and B - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hemophilia A and B - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hemophilia A and B - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hemophilia A and B - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hemophilia A and B - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hemophilia A and B - Argentina Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022